Erasca Revamps With Two In-Licensings, $160m Follow-On Offering

 
• By Joseph Haas
  
pancreatic cancer
Erasca is pursuing targeted therapies for solid tumors like pancreatic cancer • Source: Alamy
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business